Gilead’s converting Truvada PrEP users to Descovy faster than expected: analyst

One big task for Gilead Sciences’ HIV franchise in the coming year is to save some $2.5 billion in annual sales by switching as many PrEP patients as possible from Truvada to newly approved Descovy before generics hit. So far, the company’s doing a good job.